Duroferon Forðatafla 100 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

duroferon forðatafla 100 mg

aco hud nordic ab* - ferrosi sulfas - forðatafla - 100 mg

Epiduo Hlaup 0,1 % / 2,5 % Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

epiduo hlaup 0,1 % / 2,5 %

galderma nordic ab - adapalenum inn; benzoylis peroxidum - hlaup - 0,1 % / 2,5 %

Keflex Mixtúrukyrni, dreifa 50 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

keflex mixtúrukyrni, dreifa 50 mg/ml

stada nordic aps. - cefalexinum mónóhýdrat - mixtúrukyrni, dreifa - 50 mg/ml

Keflex Tafla 500 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

keflex tafla 500 mg

stada nordic aps. - cefalexinum mónóhýdrat - tafla - 500 mg

Kefzol Stungulyfs-/innrennslisstofn, lausn 1 g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

kefzol stungulyfs-/innrennslisstofn, lausn 1 g

stada nordic aps. - cefazolinum natríum - stungulyfs-/innrennslisstofn, lausn - 1 g

Mydriacyl Augndropar, lausn 10 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

mydriacyl augndropar, lausn 10 mg/ml

alcon nordic a/s - tropicamidum inn - augndropar, lausn - 10 mg/ml

Oculac Augndropar, lausn 5 % Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

oculac augndropar, lausn 5 %

alcon nordic a/s - povidonum k25 - augndropar, lausn - 5 %

Oculac án rotvarnar Augndropar, lausn 5 % Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

oculac án rotvarnar augndropar, lausn 5 %

alcon nordic a/s - povidonum k25 - augndropar, lausn - 5 %

Bimzelx Evrópusambandið - íslenska - EMA (European Medicines Agency)

bimzelx

ucb pharma s.a.   - bimekizumab - psoriasis - Ónæmisbælandi lyf - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Nuwiq Evrópusambandið - íslenska - EMA (European Medicines Agency)

nuwiq

octapharma ab - simoctocog alfa - hemophilia a - blóðstorkunarþættir - meðferð og fyrirbyggjandi blæðingar hjá sjúklingum með dreyrasýki a (meðfæddan storkuþætti viii skortur). nuwiq getur verið notað fyrir öllum aldri tekur.